1. Clinicopathological and prognostic significance of heme oxygenase-1 expression in small intestinal adenocarcinomas
- Author
-
H.K. Kim, Kyu Yun Jang, Seung-Mo Hong, Dae Woon Eom, Young Kyung Bae, and Sun-Young Jun
- Subjects
0301 basic medicine ,Pathology ,medicine.medical_specialty ,Younger age ,business.industry ,Microarray analysis techniques ,General Medicine ,medicine.disease_cause ,Pathology and Forensic Medicine ,Heme oxygenase ,03 medical and health sciences ,chemistry.chemical_compound ,030104 developmental biology ,0302 clinical medicine ,chemistry ,Tumor progression ,030220 oncology & carcinogenesis ,medicine ,Cancer research ,Immunohistochemistry ,In patient ,Carcinogenesis ,business ,Heme - Abstract
Heme oxygenase-1 (HO-1), a stress-response protein, is highly induced in various carcinomas. It is implicated in carcinogenesis and tumor progression. High HO-1 expression is associated with better prognosis of patients with colorectal and gastric cancers. Induction or inhibition of HO-1 can mediate chemo-sensitivity, therefore it might be a therapeutic target to develop anticancer agents. To define the clinicopathological and prognostic significance of HO-1 expression in small-intestinal adenocarcinomas (SIACs), immunohistochemical microarray analysis of HO-1 expression was performed for 191 surgically resected SIAC cases and results were compared with various clinicopathologic variables, including survival. HO-1 was highly expressed in 127 (66.5%) cases. Patients with high HO-1 expression were associated with younger age (P = 0.048), lower pT category (P = 0.017), and less pancreatic invasion (P = 0.047). Patients with high HO-1 expression tended to have longer overall survival (median, 38.5 months) than those with low HO-1 expression (24.5 months), although the difference in overall survival was not statistically significant (P = 0.677). In summary, high HO-1 expression is frequently observed in SIACs. It is related to favorable clinicopathologic parameters, including younger age, lower T category, and less pancreatic invasion. Therefore, HO-1 may serve as a prognostic marker and a new target to modulate chemotherapeutic effects in patients with SIACs.
- Published
- 2018
- Full Text
- View/download PDF